---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019170"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:11:57.607733+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus Q1 net loss widens to $17.7M; in-licenses CRB-701 Nectin-4 ADC

## Summary
- Net loss of $17.7M ($4.24 per share) vs $9.4M ($2.26) in Q1 2022.
- Operating expenses rose $8.8M to $17.3M, driven by $7.5M CRB-701 license upfront.
- Cash and investments $44.2M; runway expected through Q2 2024.
- In-licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 in China, US trial by mid-2024.
- CRB-601 IND on track for H2 2023; Dr. Yong Ben appointed to board March 1.

## SEC filing metadata
- accession: 0000950170-23-019170
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/0000950170-23-019170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/crbp-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019170
- JSON: https://secwatch.observer/filing/0000950170-23-019170.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019170.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2023 results: net income a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, EPS a net loss per diluted share of $4.24.
  - Period: the three months ended March 31, 2023
  - Net income: a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24
  - EPS: a net loss per diluted share of $4.24
  - Result: reported results
  source text: The Company reported a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023019170/0000950170-23-019170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.